Emergence of Streptococcus pneumoniae with very-high-level resistance to penicillin.
Penicillin resistance threatens the treatment of pneumococcal infections. We used sentinel hospital surveillance (1978 to 2001) and population-based surveillance (1995 to 2001) in seven states in the Active Bacterial Core surveillance of the Emerging Infections Program Network to document the emergence in the United States of invasive pneumococcal isolates with very-high-level penicillin resistance (MIC > or = 8 microg/ml). Very-high-level penicillin resistance was first detected in 1995 in multiple pneumococcal serotypes in three regions of the United States. The prevalence increased from 0.56% (14 of 2,507) of isolates in 1995 to 0.87% in 2001 (P = 0.03), with peaks in 1996 and 2000 associated with epidemics in Georgia and Maryland. For a majority of the strains the MICs of amoxicillin (91%), cefuroxime (100%), and cefotaxime (68%), were > or =8 microg/ml and all were resistant to at least one other drug class. Pneumonia (50%) and bacteremia (36%) were the most common clinical presentations. Factors associated with very highly resistant infections included residence in Tennessee, age of <5 or > or =65 years, and resistance to at least three drug classes. Hospitalization and case fatality rates were not higher than those of other pneumococcal infection patients; length of hospital stay was longer, controlling for age. Among the strains from 2000 and 2001, 39% were related to Tennessee(23F)-4 and 35% were related to England(14-)9. After the introduction of the pneumococcal conjugate vaccine, the incidence of highly penicillin resistant infections decreased by 50% among children <5 years of age. The emergence, clonality, and association of very-high-level penicillin resistance with multiple drug resistance requires further monitoring and highlights the need for novel agents active against the pneumococcus.
Division of Bacterial and Mycotic Diseases, National Center for Infectious Diseases, Centers for Disease Control and Prevention, Atlanta, Georgia 30333, USA.
Stephanie J
SJ
Schrag
Lesley
L
McGee
Cynthia G
CG
Whitney
Bernard
B
Beall
Allen S
AS
Craig
Miriam E
ME
Choate
James H
JH
Jorgensen
Richard R
RR
Facklam
Keith P
KP
Klugman
D015257:DNA-Cytosine Methylases / Q000235:genetics; D016521:Electrophoresis, Gel, Pulsed-Field; D006801:Humans; D008826:Microbial Sensitivity Tests; D017720:Molecular Epidemiology; D010403:Penicillin Resistance / Q000235:genetics*; D010406:Penicillins / Q000494:pharmacology; D011008:Pneumococcal Infections / Q000453:epidemiology / Q000382:microbiology*; D022242:Pneumococcal Vaccines / Q000627:therapeutic use; D011153:Population; D011159:Population Surveillance; D012307:Risk Factors; D013296:Streptococcus pneumoniae / Q000187:drug effects* / Q000235:genetics*; D014481:United States / Q000453:epidemiology
D010406:Penicillins; D022242:Pneumococcal Vaccines; C079006:DNA modification methylase XcyI; D015257:DNA-Cytosine Methylases